- Beitritt
- 20.08.09
- Beiträge
- 5.423
Die Zulassungsstudien von Pfizer
www.medrxiv.org
zeigen 15 Todesfälle bei den geimpften Personen (2 Impfungen erhalten), 14 Todesfälle bei den Personen mit Placebo, innerhalb eines Zeitraumes von Impfung bis 6 Monate nach Impfungen:

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Background BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. BNT162b2 is highly efficacious against COVID-19 and is currently authorized for emergency use or conditional approval...
zeigen 15 Todesfälle bei den geimpften Personen (2 Impfungen erhalten), 14 Todesfälle bei den Personen mit Placebo, innerhalb eines Zeitraumes von Impfung bis 6 Monate nach Impfungen:
During the blinded, controlled period, 15 BNT162b2 and 14 placebo recipients died; during the open-label period, 3 BNT162b2 and 2 original placebo recipients who received BNT162b2 after unblinding died. None of these deaths were considered related to BNT162b2 by investigators. Causes of death were balanced between BNT162b2 and placebo groups (Table S4)